Patients that have chronic myeloid leukaemia (CML) in its chronic phase and are resistant or intolerant to alternative treatment Gleevec have an 82% overall survival rate have when treated with 100mg Sprycel a daily, a study suggests.
The four-year follow-up results of a Phase III study also found that the patients given 100mg of Sprycel daily had a 66% progression-free survival rate.
The randomised, open-label, dose-optimisation study was carried out by Bristol-Myers Squibb Company, in association Otsuka Pharmaceutical, to evaluate the efficacy of Sprycel compared to Gleevec in CML patients.
Adverse events with the Sprycel treatment mainly occurred within the first 24 months.
The median time from CML onset to randomisation in patients on the 100mg once daily arm was 55 months, with 46% of these patients having had more than three years of prior Gleevec treatment.
Sprycel has been approved by the US Food and Drug Administration for the treatment of adults for all phases of chronic, accelerated, or myeloid or lymphoid blast phase CML, who have resistance or intolerance to prior therapy.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData